Table 5.14.
Drug | Route | Mechanisms | Company | Clinical trial phase | ClinicalTrials.gov identifier |
---|---|---|---|---|---|
Lenvervimab (GC1102) | IV | Monoclonal antibody | Green Cross, South Korea | 2a | NCT03801798/NCT02304315 |
Vonafexor (EYP001) | Oral | FXR agonist | Enyo Pharma, France | 1 | NCT04365933 |
ASC22 (KN035) | SC | PD-L1 pathway | Ascletis Pharma, PR China | 2a | NCT04465890 |
LTCR-H2–1 | IV | T cell immunotherapy | Lion TCR, Singapore | 1 | NCT04745403 |
IV intravenous, SC subcutaneous, N/A not applicable